Gyros Protein Technologies Introduces Gyrolab CHO-HCP E3G Kit for Impurity Testing of Biotherapeutics

Gyrolab CHO-HCP Kits quantify residual host cell proteins (HCP) from Chinese hamster ovary (CHO) cells used in bioprocessing of biotherapeutics, one of the critical analytical steps in ensuring the safety of the therapeutic. Combined with the automation, performance and high throughput of Gyrolab systems, the new kits have a broad dynamic range and show low intra- and inter-assay variation, increasing productivity in host cell protein analysis in bioprocess development. Optimized for use with the Gyrolab platforms, the new Gyrolab CHO-HCP E3G kit provides consistent and sensitive assay performance without the need for extensive assay development. With further qualification of these antibodies in the customer’s assay, using sensitive orthogonal analytical services provided by Cygnus Technologies, it is now possible to identify the coverage to individual downstream HCPs and determine if a process-specific antibody and subsequent Gyrolab custom assay is required.

The Gyrolab immunoassay platforms, Gyrolab xPand, Gyrolab xP workstation, and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, affinity, IgG titer and quantitating bioprocess-related impurities. Gyrolab technology includes optimized, ready-to-use kits, which simplify assay workflows and shorten run times. Some users have reported a 40% reduction in project times versus alternative technologies. The proprietary Gyrolab CD technology, with highly reproducible nanoliter microfluidics, is integrated with Gyrolab platforms to automate nanoliter-scale immunoassays with parallel processing, using laser-induced fluorescence detection.

Dan Calvo, CEO and president, Gyros Protein Technologies, said: “The new CHO-HCP E3G kit gives Gyrolab customers access to industry-leading analysis tools for bioanalytical and bioprocess development, incorporating Cygnus Technologies’ gold standard reagents. The new products are an important addition to our growing portfolio of ready-to-use kits for analysis in bioprocess development and QC, helping customers to maximize productivity whilst meeting performance standards required by the regulatory community.”

The new kit will be showcased at The Bioprocessing Summit 2018 on 13-17 August in Boston, MA.

ENDS

Notes to editors

For a high resolution image please contact Zyme Communications

View source version on businesswire.com: https://www.businesswire.com/news/home/20180813005360/en/